Fig. 1 · Structure

Documents & Downloads

Bufalin

Cat. No. A12022 CAS 465-21-4
Bufalin is an active component isolated from Chan Su, acts as a potent Na+/K+-ATPase inhibitor, binds to the subunit α1, α2 and α3, with Kd of 42.5, 45 and 40 nM, respectively. Anti-cancer activity.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
786-0 EC50 7.5 nM Cytotoxicity against human 786-O cells assessed as decrease in cell viability after 72 hrs by MTS assay [PMID: 30369239]
A549 IC50 0.6 μM Cytotoxicity against human A549 cells after 24 hrs by MTT assay [PMID: 24050254]
Bel-7402 IC50 7 nM Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay [PMID: 15844967]
BGC-823 IC50 4.5 x 10 Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay [PMID: 15844967]
BXPC-3 EC50 11 nM Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 72 hrs by MTS assay [PMID: 30369239]
CCRF S-180 EC50 > 20000 nM Cytotoxicity against mouse S180 cells assessed as decrease in cell viability after 72 hrs by MTS assay [PMID: 30369239]
CCRF S-180 IC50 > 50 μM Cytotoxicity against mouse S180 cells expressing mutated alpha-1 Na+/K+-ATPase assessed as growth inhibition after 48 hrs by MTT assay [PMID: 23799775]
CNE IC50 0.279 μM Cytotoxicity against human CNE1 cells assessed as growth inhibition after 48 hrs by MTT assay [PMID: 23799775]
CNE2Z IC50 0.46 μM Cytotoxicity against human CNE2Z cells assessed as growth inhibition after 48 hrs by MTT assay [PMID: 23799775]
H22 IC50 > 50 μM Cytotoxicity against mouse H22 cells expressing mutated alpha-1 Na+/K+-ATPase assessed as growth inhibition after 48 hrs by MTT assay [PMID: 23799775]
HCT-116 EC50 11 nM Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by MTS assay [PMID: 30369239]
HeLa IC50 2.8 x 10 Cytotoxicity against human HeLa cells after 72 hrs by MTT assay [PMID: 15844967]
HeLa IC50 279.9 nM Cytotoxicity activity against human HeLa cells after 48 hrs by MTT assay [PMID: 30245398]
HeLa IC50 594.2 nM Cytotoxicity activity against human HeLa cells after 24 hrs by MTT assay [PMID: 30245398]
HepG2 IC50 0.345 μM Cytotoxicity against adriamycin-resistant human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay [PMID: 23799775]
HepG2 IC50 0.589 μM Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay [PMID: 23799775]
HepG2 IC50 0.6 μM Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay [PMID: 24050254]
HepG2 EC50 35 nM Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by MTS assay [PMID: 30369239]
HL-60 IC50 < 0.01 μg/mL Cytotoxicity against human HL60 cells after 72 hrs by MTT assay [PMID: 11575946]
HUVEC EC50 12 nM Cytotoxicity against human HUVEC cells assessed as decrease in cell viability after 72 hrs by MTS assay [PMID: 30369239]

20 records · Scroll to view more

Bufalin Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Bufalin from 3 published references. In vitro models include MCF-7 cells; HepG2 cells.

Bufalin In Vitro Studies

Bufalin induced apoptosis in MCF-7 cells, as evidenced by elevated Annexin V-positive populations. In HepG2 cells, RNA sequencing showed upregulated and downregulated genes after Bufalin treatment. In bone marrow-derived macrophages incubated in Hepa1-6 conditioned medium, Bufalin priming increased the IL-12/IL-10 ratio compared with vehicle priming. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Apoptosis in MCF-7 cells

Cell-based study · MCF-7 cells [1]

MCF-7 cells were treated with Bufalin. Treatment induced apoptosis, as evidenced by elevated Annexin V-positive populations.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
apoptosis was examined by measuring Annexin V stainingReported result MCF-7 cells were treated with 20 or 50 nM Bufalin for 48 h; treatment with Bufalin induced apoptosis, as evidenced by the elevated Annexin V-positive populations.[1]

Literature-Reported Treatment Conditions

Treatment concentration
20 or 50 nM
Exposure duration
48 h
Reported limits
Not stated in the sentences used: route, vehicle, control.
Methods and source locations

Compound reported in the paper: Bufalin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Bufalin’s anti-cancer effects in ER+ cells are dependent on ERα (S70); Methods > Flow-cytometric analysis of apoptosis (S172); Fig. 6 legend (S280)

apoptosis was examined by measuring Annexin V staining: apoptosis was examined by measuring Annexin V staining — Results > Bufalin’s anti-cancer effects in ER+ cells are dependent on ERα (S70); Fig. 6 legend (S280)

Gene expression changes in liver cancer cells

Cell-based study · HepG2 cells [2]

HepG2 cells were treated with Bufalin at 400 nM for 12 h, with vehicle as the control. RNA sequencing showed that 3000 genes were upregulated and 2450 genes were downregulated after treatment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
RNA sequencingdifferentially expressed genes 3000 genes were upregulated, while 2450 genes were downregulated[2]

Literature-Reported Treatment Conditions

Treatment concentration
400 nM
Exposure duration
12 h
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: Bufalin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > E2F2 degradation regulates the transcription of oncogenic genes (S192, S193); Fig. 6 legend (S238)

RNA sequencing: RNA sequencing; comparator: vehicle (control group) — Results > E2F2 degradation regulates the transcription of oncogenic genes (S192, S193)

Cytokine ratio changes in bone marrow-derived macrophages

Cell-based study · Bone marrow-derived macrophages (BMDMs) were isolated from the femurs of C57BL/6 mice [3]

Bone marrow-derived macrophages from C57BL/6 mice were incubated with Bufalin or vehicle in Hepa1-6 conditioned medium for 48 hours in a design including recombinant M-CSF. The IL-12/IL-10 ratio increased from 0.3 to 8 with Bufalin priming compared with vehicle priming.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
The levels of interleukin (IL)-12 and IL-10 in the supernatant of vehicle-primed or bufalin-primed macrophages were measured by ELISA, and the IL-12/IL-10 ratio was calculated.IL-12/IL-10 ratio IL-12/IL-10 ratio increased from 0.3 to 8[3]

Literature-Reported Treatment Conditions

Exposure duration
48 hours
Method
incubated with bufalin or vehicle in the Hepa1-6 CM
Co-treatment
Other interventions in this design: Hepa1-6 conditioned medium (CM); recombinant M-CSF 20 ng/mL. Compound effect isolated by the comparison: vehicle-primed or bufalin-primed macrophages.
Reported limits
Not stated in the sentences used: dose, vehicle.
Methods and source locations

Compound reported in the paper: Bufalin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Generation of bone marrow-derived macrophages and macrophage polarization (S25); Results > Bufalin reprograms M2 macrophages to M1 (S77, S81); Figure 3 legend (S159, S164)

The levels of interleukin (IL)-12 and IL-10 in the supernatant of vehicle-primed or bufalin-primed macrophages were measured by ELISA, and the IL-12/IL-10 ratio was calculated.: The levels of interleukin (IL)-12 and IL-10 in the supernatant of vehicle-primed or bufalin-primed macrophages were measured by ELISA, and the IL-12/IL-10 ratio was calculated.; comparator: vehicle-primed — Results > Bufalin reprograms M2 macrophages to M1 (S81); Figure 3 legend (S164)

Bufalin In Vivo Studies

C57BL/6 mice inoculated with Hepa1-6-Luc cells in the liver received Bufalin intraperitoneally at 10 μg/kg every other day for 3 weeks. At the end of 30 days of observation, survivors were reported in the Bufalin group, while none were reported in the anti-PD-1 Ab or vehicle groups. [3]

Survival in a mouse liver tumor model

Animal study · Hepa1-6-Luc cells were inoculated into the livers of C57BL/6 mice [3]

C57BL/6 mice inoculated with Hepa1-6-Luc cells in the liver received Bufalin intraperitoneally at 10 μg/kg every other day for 3 weeks. At the end of 30 days of observation, survivors were reported in the Bufalin group, while none were reported in the anti-PD-1 Ab or vehicle groups.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Overall survivalOverall survival two out of five in bufalin treatment[3]

Conditions shared by the study groups

Route
intraperitoneally
Treatment course
every other day in 3 weeks
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Bufalin 10 μg/kgvehicletwo out of five in bufalin treatment, none in anti-PD-1 Ab and vehicle, in the end of 30 days observation[3]
Bufalin 10 μg/kg
Model: Hepa1-6-Luc cells were inoculated into the livers of C57BL/6 mice
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Bufalin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Animal experiment (S6); Results > Bufalin enhances the anti-HCC effect in combination with anti-PD-1 antibody (S133, S134); Figure 7 legend (S203)

Overall survival: Overall survival; comparator: vehicle — Results > Bufalin enhances the anti-HCC effect in combination with anti-PD-1 antibody (S134); Figure 7 legend (S203)

Bufalin 10 μg/kg · Materials and methods > Animal experiment (S6); Results > Bufalin enhances the anti-HCC effect in combination with anti-PD-1 antibody (S134)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 465-21-4
Formula C24H34O4
Molecular Weight 386.5
SMILES
C[C@]12CC[C@@H](C[C@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@@]3(CC[C@@H]4C5=COC(=O)C=C5)O)C)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 72 mg/mL (186.28 mM)
Water <1 mg/mL
Ethanol 37 mg/mL (95.72 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Bufalin Research References

  1. [1] Jiang S, Liu K, Jiang T, et al. Harnessing artificial intelligence to identify Bufalin as a molecular glue degrader of estrogen receptor alpha. Nat Commun (2025). PMID: 40846852 DOI: 10.1038/s41467-025-62288-7 Source material
  2. [2] Liu TT, Yang H, Zhuo FF, et al. Atypical E3 ligase ZFP91 promotes small-molecule-induced E2F2 transcription factor degradation for cancer therapy. EBioMedicine (2022). PMID: 36375317 DOI: 10.1016/j.ebiom.2022.104353 Source material
  3. [3] Yu Z, Li Y, Li Y, et al. Bufalin stimulates antitumor immune response by driving tumor-infiltrating macrophage toward M1 phenotype in hepatocellular carcinoma. J Immunother Cancer (2022). PMID: 35618286 DOI: 10.1136/jitc-2021-004297 Source material

Added to your cart

View Cart Checkout
Loading...